Relative Value

2MT price has not been updated for more than 6 years. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of 2MT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2MT Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
5.9
Median 5Y
6
Industry
7.8
Forward
8.2
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-6.3
Industry
24.1
Forward
-21.7
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-10.1
Industry
21.8
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
23.8
vs History
vs Industry
Median 3Y
-119.4
Median 5Y
-116.3
Industry
3.3
vs History
vs Industry
Median 3Y
6.3
Median 5Y
6.3
Industry
8
Forward
8.7
vs History
vs Industry
Median 3Y
25
Median 5Y
25
Industry
10.3
vs History
vs Industry
Median 3Y
-9.4
Median 5Y
-9.1
Industry
6.3
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-8.9
Industry
6.7
vs History
vs Industry
Median 3Y
-11.1
Median 5Y
-10.8
Industry
7.9
vs History
vs Industry
Median 3Y
-10.8
Median 5Y
-10.5
Industry
6.3
vs History
vs Industry
Median 3Y
6
Median 5Y
5.9
Industry
5.5

Multiples Across Competitors

2MT Competitors Multiples
Athenex Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Athenex Inc
F:2MT
715.7m EUR 6.4 -7 -10.1 -9.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 675 001.5 -160 052.3 -194 354.5 -192 136.7
US
Abbvie Inc
NYSE:ABBV
406.3B USD 6.8 173 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.7B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD 5.4 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 092 -533.8 -581.3 -565.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD 16.5 1 212.2 163.5 198.2
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.2 59.8
P/E Multiple
Earnings Growth PEG
US
A
Athenex Inc
F:2MT
Average P/E: 191.6
Negative Multiple: -7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 052.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 212.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Athenex Inc
F:2MT
Average EV/EBITDA: 40.4
Negative Multiple: -10.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 354.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Athenex Inc
F:2MT
Average EV/EBIT: 46.6
Negative Multiple: -9.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 136.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.2
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A